Author name: Leonardo Arias

Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly year over year and quarter over quarter, based on BioSpace tallies.

Aunque las condiciones superficiales de Marte son extremadamente adversas para la vida terrestre —radiación intensa, temperaturas muy bajas, atmósfera delgada, falta de agua líquida estable—, investigaciones recientes demuestran que ciertos organismos podrían …

The CMS administrator’s comments at an industry event in D.C. on Wednesday reflect the difficult tightrope regulators in the Trump administration walk as they pursue MA reform.

Novo Nordisk struck another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work.

This webinar, tailored for scientists in academia, biotech, and pharma, explores how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.

As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and beef up the review process for deals involving private equity firms.

Stereotaxis CEO David Fischel said the precision, stability and safety profile of robotics are a good fit for pulsed field ablation.

Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain.

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.